Connect with us

Published

on

Prenuvo’s clinic in New York City, New York.

Courtesy of Prenuvo

Preventative health startup Prenuvo on Thursday announced it will offer three new health assessments in addition to its flagship full-body MRI scan.

The company is launching a detailed blood test, neurological scan and body composition analysis that was approved by the U.S. Food and Drug Administration in recent weeks. Prenuvo said it wants to give customers an accurate picture of their health, and that its patients have been asking for more. 

“They have come to the understanding and realization that the health system is not serving their needs as it relates to keeping them healthy,” Prenuvo CEO Andrew Lacy told CNBC in an interview. “Consumers are increasingly looking for alternate solutions so they can stay on top of their health.”

Prenuvo exploded in popularity because of its $2,500 full-body MRI scan that has been lauded by celebrities like Kim Kardashian. The company can check for hundreds of conditions like cancer, multiple sclerosis and aneurysms once its custom, FDA-approved MRI machines scan a person’s body in an hour.

The full-body scan and the new blood test, neurological scan and body composition report will be packaged together and offered to customers for $3,999, Lacy said.  

Prenuvo MRI machine

Courtesy of Prenuvo

Prenuvo has surpassed 110,000 members, and the company generated $100 million in revenue last year. It owns and operates 17 clinics across North America and plans to expand to 15 more locations in the coming months, including sites in Europe and Australia, Lacy said. 

Lacy said Prenuvo has grown quickly but is profitable.

Prenuvo has faced criticism for its steep prices, and some medical experts have warned that the scans aren’t meant to replace targeted screenings and could cause patients to seek out unnecessary care.   

Investors are bullish anyway. 

The company announced Thursday that it closed a $120 million funding round, co-led by Left Lane Capital, Forerunner Ventures and its existing investor, Felicis. Prenuvo will use its fresh financing to support its product expansion, its push into new regions and explore applications for artificial intelligence.

A competing full-body MRI startup Ezra announced a $21 million funding round last February.

Read more CNBC tech news

Prenuvo has the largest repository of whole-body MRI imaging in the world, Lacy said, which means there are lots of opportunities for the company to build models that make its exams more accurate and its 80 board-certified radiologists more efficient.

The company’s new body composition analysis, which is called the Prenuvo Body Composition report, uses AI to assess the volume and symmetry of muscles and the distribution of fat in the abdomen. Lacy said muscle size and distribution is a leading indicator of mobility, and fat distribution can affect risk of metabolic disease and cardiovascular disease. 

“This is really, really important information for patients who are looking to proactively manage their health,” Lacy said.

Patients will not need to undergo any additional imaging for the Prenuvo Body Composition report.

Prenuvo MRI machine

Courtesy of Prenuvo

Prenuvo’s new brain health scan is also imaging based, and it gives patients a glimpse into their cognitive health and function, the company said. The scan uses neurological sequences that Prenuvo developed in-house to assess blood flow, the brain’s microvascular structure and identify any repetitive trauma from activity like sports. 

It requires an additional 10 minutes of imaging, and the sequences are already FDA approved, Lacy said.  

The blood assessment is new territory for the company, and it will check patients’ biomarkers to provide insights into hormonal, cardiovascular, metabolic and immune health. Lacy said the test could help detect leukemia, a blood cancer that can’t be identified with imaging, for instance. 

“Blood and imaging together is just incredibly powerful,” Lacy said. “It’s not a case of one plus one equals two, it’s one plus one equals five.”

Initially, a phlebotomist, a person who is trained to draw blood, will come to patients’ homes to collect the blood sample, Prenuvo said. The company also plans to draw blood inside its facilities eventually, but Lacy wants to provide a premium experience that is as calming and comfortable as possible.

Patients can access the new assessments at Prenuvo’s Silicon Valley, Los Angeles and New York locations starting Thursday. Additional locations will offer the tests this spring, the company said. 

“No one is going to care about your health more than you do,” Lacy said. “When you diagnose things early, it’s empowering. You can do something about it.”

Watch: John Hancock CEO talks collaboration with Prenuvo and focus on longevity

John Hancock CEO talks collaboration with Prenuvo and focus on longevity

Continue Reading

Technology

Meta approached Perplexity before massive Scale AI deal

Published

on

By

Meta approached Perplexity before massive Scale AI deal

Meta approached Perplexity before massive Scale AI deal

Meta approached artificial intelligence startup Perplexity AI about a potential takeover bid before ultimately investing $14.3 billion into Scale AI, CNBC confirmed on Friday.

The two companies did not finalize a deal, according to two people familiar with the matter who asked not to be named because of the confidential nature of the negotiations.

One person familiar with the talks said it was “mutually dissolved,” while another person familiar with the matter said Perplexity walked away from a potential deal.

Bloomberg earlier reported the talks between Meta and Perplexity. Perplexity declined to comment. Meta did not immediately respond to CNBC’s request for comment.

Meta’s attempt to purchase Perplexity serves as the latest example of Mark Zuckerberg‘s aggressive push to bolster his company’s AI efforts amid fierce competition from OpenAI and Google parent Alphabet. Zuckerberg has grown agitated that rivals like OpenAI appear to be ahead in both underlying AI models and consumer-facing apps, and he is going to extreme lengths to hire top AI talent, as CNBC has previously reported.

Read more CNBC reporting on AI

Meta now has a 49% stake in Scale after its multibillion-dollar investment, though the social media company will not have any voting power. Scale AI’s founder Alexandr Wang, along with a small number of other Scale employees, will join Meta as part of the agreement.

Earlier this year, Meta also tried to acquire Safe Superintelligence, which was reportedly valued at $32 billion in a fundraising round in April, as CNBC reported on Thursday.

Daniel Gross, the CEO of Safe Superintelligence, and former GitHub CEO Nat Friedman are joining Meta’s AI efforts, where they will work on products under Wang. Gross runs a venture capital firm with Friedman called NFDG, their combined initials, and Meta will get a stake in the firm.

OpenAI CEO Sam Altman said on the latest episode of the “Uncapped” podcast, which is hosted by his brother, that Meta had tried to poach OpenAI employees by offering signing bonuses as high as $100 million with even larger annual compensation packages.

“I’ve heard that Meta thinks of us as their biggest competitor,” Altman said on the podcast. “Their current AI efforts have not worked as well as they have hoped and I respect being aggressive and continuing to try new things.”

–CNBC’s Kate Rooney contributed to this report

WATCH: Meta tried to buy Perplexity before Scale AI deal

Continue Reading

Technology

Why ether ETF inflows have come roaring back from the dead

Published

on

By

Why ether ETF inflows have come roaring back from the dead

Omar Marques | Lightrocket | Getty Images

Ether ETFs have finally come to life this year after some started to fear they may be becoming zombie funds.

Collectively, the funds tracking the price of spot ether are on pace for their sixth consecutive week of inflows and eight positive week in the last nine, according to SoSoValue.

The second largest cryptocurrency has become more attractive to institutions in recent weeks largely due to recent regulatory momentum in the U.S. around stablecoins – many of which run on the Ethereum network – the successful IPO of Circle, the issuer of the second-largest stablecoin; and new leadership at the Ethereum Foundation.

“What we’re seeing is institutional recalibration,” said Ben Kurland, CEO at crypto charting and research platform DYOR. “After the initial ETH ETF approval fizzled without a price pop, smart money started quietly building positions. They’re betting not on price momentum but on positioning ahead of utility unlocks like staking access, options listings, and eventually inflows from retirement platforms.”

The first year of ether ETFs, which launched in July 2024, has been characterized by weak demand. While the funds have had spikes in inflows, they’ve trailed far behind bitcoin ETFs in both inflows and investor attention – amassing about $3.9 billion in net inflows since listing versus bitcoin ETFs’ $36 billion in their first year of trading.

“With increasing acceptance of crypto on Wall Street, especially now as a means for payments and remittances, investors are being drawn to ETH ETFs,” said Chris Rhine, head of liquid active strategies at Galaxy Digital.

Additionally, he added, the CME basis on ether – or the price difference between ether futures and the spot price – is higher than that of bitcoin, giving arbitrageurs an opportunity to profit by going long on ether ETFs while shorting futures (a common trading strategy) and contributing to the uptrend in ether ETF inflows.

Stock Chart IconStock chart icon

hide content

Ether (ETH) 1 month

Despite the uptrend in inflows, the price of ether itself is negative for this month and flat over the past month.

For the year, it’s down 25% as it’s been suffering from an identity crisis fueled by uncertainty about Ethereum’s value proposition, weaker revenue since its last big technical upgrade and increasing competition from Solana. Market volatility driven by geopolitical uncertainty this year has not helped.

In March, Standard Chartered slashed its ether price target by more than half. However, the firm also said the coin could still see a turnaround this year.

Since last week’s big spike in inflows, they’ve “slowed but stayed net positive, suggesting conviction, not hype,” Kurland said. “The market looks like a heart monitor, but the buyers are treating it like a long-term infrastructure bet.”

Don’t miss these cryptocurrency insights from CNBC Pro:

Continue Reading

Technology

Chip stocks fall on report U.S. could terminate waivers for Taiwan Semi and others

Published

on

By

Chip stocks fall on report U.S. could terminate waivers for Taiwan Semi and others

A motorcycle is seen near a building of the Taiwan Semiconductor Manufacturing Company (TSMC), which is a Taiwanese multinational semiconductor contract manufacturing and design company, in Hsinchu, Taiwan, on April 16, 2025.

Daniel Ceng | Anadolu | Getty Images

Semiconductor stocks declined Friday following a report that the U.S. is weighing measures that would terminate waivers allowing some chipmakers to send American technology to China.

Commerce Department official Jeffrey Kessler told Samsung Electronics, SK Hynix and Taiwan Semiconductor this week that he wanted to cancel their waivers, which allow them to send U.S. chipmaking tech to their factories in China, the Wall Street Journal reported, citing people familiar with the matter.

The VanEck Semiconductor ETF declined about 1%. Nvidia, Qualcomm and Marvell Technology fell about 1%, while Taiwan Semiconductor slipped about 2%.

The latest reported move by the Commerce Department comes as the U.S. and China hold an unsteady truce over tariffs and trade, with chip controls a key sticking point.

Read more CNBC tech news

The countries agreed to the framework of a second trade agreement in London days ago after relations soured following the initial tariff pause in May.

The U.S. issued several chip export changes after the May pause that rattled relations, with China calling the rules “discriminatory.”

U.S. chipmakers have been hit with curbs over the last few years, limiting the ability to sell advanced artificial intelligence chips to China due to national security concerns.

During its earnings report last month, Nvidia said the recent export restriction on its China-bound H20 chips hindered sales by about $8 billion.

Nvidia CEO Jensen Huang told investors on an earnings call that the $50 billion market in China for AI chips is “effectively closed to U.S. industry.” During a CNBC interview in May, he called getting blocked from China’s AI market a “tremendous loss.”

Read the full WSJ report here.

WATCH: U.S. prepares action targeting allies’ ability to ship American chip-making equipment to China

U.S. prepares action targeting allies' ability to ship American chip-making equipment to China

Continue Reading

Trending